Supernus製藥 SUPN 深 滬
等待開盤 12-11 09:30:00 美东时间
46.16
+0.740
+1.63%
華盛通- 最 高46.90
- 今 開45.62
- 成交量 66.35万股
- 最 低 45.43
- 昨 收 45.42
- 總市值 25.88亿
- 52周最高 57.65
- 市盈率 靜 34.97
- 換手率 1.18%
- 52周最低 29.16
- 委 比 -91.41%
- 總股本 5607.31万
- 歷史最高 61.25
- 量 比 1.11
- 振 幅 3.24%
- 歷史最低 4.30
- 每 手 1
- 風險率 6.78%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股盘后 | Supernus制药跌11.14%
Supernus制药预计2025年11月发布财报，预期每股收益0.62美元，营收1.8096亿美元。公司今年前两季度业绩均未达预期，第二季度收入同比下降1.71%，主要开发中枢神经系统疾病药物，包括癫痫和帕金森病等治疗药物。
11-05 05:43
Supernus Pharmaceuticals shares are trading lower. The company reported Q3 financial results.
Supernus Pharmaceuticals shares are trading lower. The company reported Q3 fina...
11-05 05:40
Earnings Scheduled For November 4, 2025
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
A Preview Of Supernus Pharmaceuticals's Earnings
Supernus Pharmaceuticals (NASDAQ:SUPN) is gearing up to announce its quarterly ...
11-04 02:02
美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
10-30 14:22
Supernus a new buy at BofA on 'underappreciated' CNS assets
BofA Securities has initiated coverage of Supernus Pharmaceuticals (SUPN) at buy saying that the market is not fully appreciating the company's portfolio of central nervous system drugs. The bank set ...
10-30 02:37
华尔街顶级分析师最新评级报告：联合健康遭下调
华尔街最受关注、且能影响市场走势的研究评级报告现已汇总于此。以下是由 The Fly 整理的今日投资者需重点关注的评级信息。 五大评级上调案例 思佳讯...
10-29 22:12
美股大行评级 | 上调目标价！特斯拉、赛默飞世尔、拉姆研究、波士顿科学、安诺电子、金沙集团等获众多机构评级
今日重点评级关注：摩根士丹利：维持Viking Therapeutics"超配"评级，目标价从98美元升至102美元；摩根大通：维持IDEAYA Biosciences"超配"评级，目标价从74美元升至79美元
10-24 09:51
Deep Dive Into Supernus Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)
Ratings for Supernus Pharmaceuticals (NASDAQ:SUPN) were provided by 5 analysts ...
10-24 05:02
TD Cowen Maintains Buy on Supernus Pharmaceuticals, Raises Price Target to $60
TD Cowen analyst Stacy Ku maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Buy and raises the price target from $45 to $60.
10-23 23:20
